Safety and Efficacy of Subcutaneously Administered Efalizumab in Adults with Moderate-to-Severe Hand and Foot PsoriasisAn Open-Label Study

被引：0

作者：

Rajat Varma

Jennifer A. Cafardi

Wendy Cantrell

Craig Elmets

机构：

[1] University of Alabama Medical Center,UAB Department of Dermatology

来源：

American Journal of Clinical Dermatology | 2008年 / 9卷

关键词：

Psoriasis; Plaque Psoriasis; Dermatology Life Quality Index; Acitretin; Efalizumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Introduction: Hand and foot psoriasis may be more disabling than psoriasis at other body locations because of its interference with daily functional activities. Most treatment options have limited efficacy, short duration of response, toxicity, intolerability, or inconvenience.

引用

页码：105 / 109

页数：4

共 50 条

[41] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
Cork, M. J.
Thaci, D.
Davis, J. D.
Zhang, Q.
Akinlade, B.
Graham, N. M. H.
Pirozzi, G.
Bansal, A.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 155 - 155
[42] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
Cork, M. J.
Thaci, D.
Davis, J. D.
Zhang, Q.
Akinlade, B.
Graham, N. M. H.
Pirozzi, G.
Bansal, A.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 67 - 68
[43] Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO)
Ayala, Fabio
Lambert, Julien
JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (04) : 304 - 311
[44] Laboratory safety of long-term dupilumab treatment in a 5-year open-label extension study of adults with moderate-to-severe atopic dermatitis
Beck, L. A.
Bissonnette, R.
Deleuran, M.
Nakahara, T.
Galus, R.
Khokhar, F. A.
Coleman, A.
Gherardi, G.
Chen, Z.
Avetisova, E.
Dubost-Brama, A.
Shabbir, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
[45] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study
Blauvelt, Andrew
Wollenberg, Andreas
Beck, Lisa A.
Chen, Zhen
Zhang, Meng
Khokhar, Faisal A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB142 - AB142
[46] Efficacy and Safety of Neauvia Intense in Correcting Moderate-to-Severe Nasolabial Folds: A Post-Market, Prospective, Open-Label, Single-Centre Study
Zerbinati, Nicola
Platkowska, Anna
Guida, Stefania
Stabile, Giorgio
Mocchi, Roberto
Barlusconi, Chiara
Sommatis, Sabrina
Garutti, Leonardo
Rauso, Raffaele
Cipolla, Giovanna
Bettolini, Luca
Bighetti, Stefano
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2024, 17 : 1351 - 1363
[47] An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema
Weatherhead, S. C.
Wahie, S.
Reynolds, N. J.
Meggitt, S. J.
BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) : 346 - 351
[48] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the open-label run-in period of JADE REGIMEN
Lebwohl, M. G.
Worm, M.
Gold, L. F. Stein
Bangert, C.
Schmid-Grendelmeier, P.
Khan, T.
Biswas, Pinaki
DiBonaventura, M.
Chan, G.
Terry, K.
Valdez, H.
Clibborn, C.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E73 - E74
[49] Long-term safety and efficacy of ropinirole in moderate-to-severe RLS: Results of two 52-week, open-label studies
Dreykluft, T.
Garcia-Borreguero, D.
Lee, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 96 - 96
[50] Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
Saeki, H.
Nakagawa, H.
Ishii, T.
Morisaki, Y.
Aoki, T.
Berclaz, P. -Y.
Heffernan, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) : 1148 - 1155

← 1 2 3 4 5 →